Literature DB >> 6484196

Immunotherapy of patients with glioma: fact, fancy, and future.

M S Mahaley, G Y Gillespie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6484196     DOI： 10.1159/000408241

Source DB:  PubMed          Journal:  Prog Exp Tumor Res        ISSN： 0079-6263


× No keyword cloud information.
  4 in total

1.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Authors:  S K Sankhla; J S Nadkarni; S N Bhagwati
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

Review 3.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma.

Authors:  C A Kruse; M C Molleston; E P Parks; P M Schiltz; B K Kleinschmidt-DeMasters; W F Hickey
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.